Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. Issue 19 (24th July 2020)

• Record Type: Journal Article
• Authors: Ailawadhi, Sikander; Jagannath, Sundar; Lee, Hans C.; Narang, Mohit; Rifkin, Robert M.; Terebelo, Howard R.; Durie, Brian G. M.; Toomey, Kathleen; Hardin, James W.; Gasparetto, Cristina J.; Wagner, Lynne; Omel, James L.; He, Mia; Yue, Lihua; Flick, Elizabeth Dawn; Agarwal, Amit; Abonour, Rafat
• Is Part Of: Cancer. Volume 126:Issue 19(2020)
• Page Start: 4332
• Page End: 4340
• Publication Date: 2020-07-24
• Subjects: African American -- myeloma -- race -- treatment -- survival; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33089
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: Studies have reported racial disparities in access to and use of multiple myeloma (MM) treatments between African American (AA) and White patients. Although AA patients demonstrate longer disease‐specific survival, this has not uniformly translated into improved survival over time. The association between race and treatment patterns and survival outcomes was analyzed using data from the Connect MM Registry. Methods: The Connect MM Registry is a large US, multicenter, prospective observational cohort study of patients with newly diagnosed MM. Patients who received first‐line (1L) stem cell transplantation (SCT) or who did not receive SCT (non‐SCT or non–stem cell transplantation [NSCT]) were grouped by raceEffects of race and transplantation status on the use of triplet treatment were estimated using logistic regression. Results: Treatment patterns in 1L (types and duration of induction, posttransplantation maintenance) were similar between AA and White patients. SCT rates in 1L (32% vs 36%) and triplet treatment use (AA: 44% for NSCT patients and 72% for SCT patients; and White: 48% for NSCT patients and 72% for SCT patients) during first induction were similar. No significant effect of race or transplantation status on 1L triplet treatment use was observed. Race was not found to be associated with survival outcomes among patients who underwent NSCT; however, AA patients who received SCT had significantly longer overall survival compared with White patients who underwent SCT (not reached vs 88.2 months; hazard ratio, 0.56; 95% CI, 0.35‐0.89 [ P = .0141]). Conclusions: AA and White patients were found to have similar treatment patterns in the Connect MM Registry, suggesting that both groups had equal access to health care. In this real‐world setting, AA patients received standard‐of‐care treatment, which might have contributed to better MM‐specific survival compared with White patients. Abstract : Real‐world data from the mostly community‐based Connect MM Registry demonstrated that African American patients have multiple myeloma treatment patterns that are similar to those of White patients. Similar (progression‐free survival) and better (overall survival) survival outcomes are reported in African American individuals.